Download Files:
Products Details
Product Description
– LXRβ agonist-4 is a potent, orally active Liver X receptors (LXRs) inhibitor with an IC50 value of 0.0078 μM for LXRβ. LXRβ agonist-4 inhibits RANKL-induced osteoclast differentiation and bone resorption. LXRβ agonist-4 can be used in research of osteoporosis[1].
Web ID
– HY-152262
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C31H31FN2O7S
References
– [1]Chen H, et, al. Discovery of Spiro[pyrrolidine-3,3′-oxindole] LXRβ Agonists for the Treatment of Osteoporosis. J Med Chem. 2023 Jan 12;66(1):752-765.
Molecular Weight
– 594.65
SMILES
– O=C(N1CC[C@@]2(C3=CC=CC=C3NC2=O)[C@H]1C4=CC(F)=CC(C5=CC(S(=O)(C)=O)=C(C=C5)C(OC)=O)=C4)OC(C)(C)C
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– LXR
Pathway
– Metabolic Enzyme/Protease;Vitamin D Related/Nuclear Receptor
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
